BioSpace News Archive

RLDatix, the leading global provider of healthcare operations software and services that drive safer care, announced today that it has entered into a definitive agreement to acquire Porzio Life Sciences.

SURGE Therapeutics (SURGE) today announced the completion of a $26 million Series A financing led by Camford Capital, with participation from Khosla Ventures, Intuitive Ventures, Pitango HealthTech, 8VC, Alumni Ventures, and the Cancer Research Institute.

Verge Genomics, a tech-enabled drug discovery company pioneering the use of artificial intelligence (AI) and human data to develop new drugs, announced today that John Applegate will join the company as Chief Financial Officer.

Aviceda Therapeutics, a private company located in Cambridge, MA with a Phase II ready ophthalmic lead product for geographic atrophy secondary to dry AMD announced, , Patrick Healy, founding CEO of Trial Runners, will join their management team consisting of Key Opinion Leaders in the field of Ophthalmology.

Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, today announced the dosing of the first patient in the expansion cohorts of its ongoing Phase 1 study for IO-108.

Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”) today announced it has entered into an option agreement with Exacis Biotherapeutics Inc. (“Exacis”) granting Eterna the right to negotiate an exclusive, worldwide license to develop and commercialize up to four iPS cell-derived natural killer cell (“iNK”) and/or T cell (“iT”) programs for hematologic malignancies and solid tumors.

Today, Enochian BioSciences (the Company) announced that it was awarded a U.S. patent for its proprietary cancer treatment platform that could potentially be used to induce life-long remission from some of the world’s deadliest solid tumors.

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it will host an update call on its Phase 3 REGAL clinical trial of galinpepimut-S (GPS) in patients with acute myeloid leukemia (AML) on November 14, 2022.

The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, has been awarded the Eagle Award for the second consecutive year for its outstanding leadership, professionalism, integrity and dedication to advancing the clinical research profession through strong partnerships with research sites.

Jaguar Health today announced that the European Commission has adopted the decision to grant Orphan Drug Designation (ODD) for crofelemer for the indication of microvillus inclusion disease (MVID), a rare congenital diarrheal disorder (CDD) condition.